IL22 and breast cancer: By using an IL-22 knockout BC mouse model, Katara and collaborators [108] showed that IL-22 knockout led to the arrest of the malignant transition stage through the downregulation of epithelial–mesenchymal transition (EMT)-associated transcription factors and reduced tumor growth.